[1]陈金华.恩格列净对2型糖尿病患者血糖水平及胰岛素抵抗的影响[J].医学信息,2024,37(18):96-99.[doi:10.3969/j.issn.1006-1959.2024.18.018]
　CHEN Jin-hua.Effect of Empagliflozin on Blood Glucose Level and Insulin Resistance in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2024,37(18):96-99.[doi:10.3969/j.issn.1006-1959.2024.18.018]
点击复制

恩格列净对2型糖尿病患者血糖水平及胰岛素抵抗的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年18期
页码:
96-99
栏目:
论著
出版日期:
2024-09-15

文章信息/Info

Title:
Effect of Empagliflozin on Blood Glucose Level and Insulin Resistance in Patients with Type 2 Diabetes Mellitus
文章编号:
1006-1959（2024）18-0096-04
作者:
陈金华
鹰潭市余江区人民医院内一科，江西 鹰潭 335200
Author(s):
CHEN Jin-hua
The First Department of Internal Medicine,Yujiang District People’s Hospital,Yingtan 335200,Jiangxi,China
关键词:
恩格列净; 2型糖尿病; 血糖水平; 胰岛素抵抗
Keywords:
Empagliflozin; Type 2 diabetes mellitus; Blood glucose level; Insulin resistance
分类号:
R587.1
DOI:
10.3969/j.issn.1006-1959.2024.18.018
摘要:
目的 研究恩格列净对2型糖尿病患者血糖水平及胰岛素抵抗的影响。方法 选取2020年4月-2023年4月在我院诊治的72例2型糖尿病患者为研究对象，采用随机数字表法分为对照组（n=36）和观察组（n=36），对照组采用盐酸二甲双胍片治疗，观察组在对照组基础上给予恩格列净治疗，比较两组临床疗效、血糖指标[空腹血糖（FPG）、餐后2h血糖（2hPG）、糖化血红蛋白（HbA1c）]、胰岛素抵抗指数（HOMA-IR）、空腹胰岛素（FIns）、血脂指标[总胆固醇（TC）、三酰甘油（TG）]、不良反应发生率。结果 观察组治疗总有效率为94.44%，高于对照组的83.33%（P＜0.05）；两组FPG、2hPG、HbA1c均低于治疗前，且观察组低于对照组（P＜0.05）；两组HOMA-IR均低于治疗前，FIns均高于治疗前，且观察组HOMA-IR低于对照组，FIns高于对照组（P＜0.05）；两组TC、TG均低于治疗前，且观察组低于对照组（P＜0.05）；观察组不良反应发生率为5.56%，低于对照组的13.89%（P＜0.05）。结论 恩格列净治疗2型糖尿病疗效确切，可促进血糖水平控制，降低胰岛素抵抗，改善血脂指标水平，且可降低不良反应发生率，是一种有效、安全的药物，值得临床应用。
Abstract:
Objective To study the effect of empagliflozin on blood glucose level and insulin resistance in patients with type 2 diabetes mellitus.Methods A total of 72 patients with type 2 diabetes ellitus who were diagnosed and treated in our hospital from April 2020 to April 2023 were selected as the research objects. They were divided into control group (n=36) and observation group (n=36) by random number table method. The control group was treated with metformin hydrochloride tablets, and the observation group was treated with empagliflozin on the basis of the control group. The clinical efficacy, blood glucose indexes [fasting blood glucose (FPG), 2-h postprandial blood glucose (2hPG), glycosylated hemoglobin (HbA1c)], insulin resistance index (HOMA-IR), fasting insulin (FIns), blood lipid indexes [total cholesterol (TC), triglyceride (TG)] and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 94.44%, which was higher than 83.33% in the control group (P<0.05). FPG, 2hPG and HbA1c in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). HOMA-IR in the two groups was lower than that before treatment, FIns was higher than that before treatment, and HOMA-IR in the observation group was lower than that in the control group, FIns was higher than that in the control group (P<0.05). TC and TG in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was 5.56%, which was lower than 13.89% in the control group (P<0.05).Conclusion Empagliflozin is effective in the treatment of type 2 diabetes mellitus, which can promote the control of blood glucose level, reduce insulin resistance, improve blood lipid index level, and reduce the incidence of adverse reactions. It is an effective and safe drug, which is worthy of clinical application.

参考文献/References:

[1]刘玉溥,曾芳馨,彭祖江,等.西格列汀片联合地特胰岛素注射液治疗老年2型糖尿病的临床研究[J].中国临床药理学杂志,2017,33(15):1415-1417.[2]张欣荣,薛有平,张凤强,等.恩格列净联合格列齐特治疗2型糖尿病的临床研究[J].现代药物与临床,2022,37(7):1565-1569.[3]薛灏颖,洪霞飞,王苏,等.2型糖尿病患者血清betatrophin水平与尿白蛋白肌酐比的相关性研究[J].医学研究生学报,2017,30(4):389-393.[4]Wang L,Gao P,Zhang M,et al.Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013[J].JAMA,2017,317(24):2515-2523.[5]黄志龙,都渝,赵君.GLP-1激动剂联合替格瑞洛对2型糖尿病合并冠心病患者血清YKL-40及PPARγ的影响[J].中南医学科学杂志,2021,49(5):559-563.[6]赵维纲.《中国老年2型糖尿病防治临床指南(2022年版)》解读[J].协和医学杂志,2022,13(4):574-580.[7]周伟.胰岛素联合达格列净治疗2型糖尿病的临床疗效及其安全性[J].临床合理用药杂志,2021,14(21):81-83.[8]辛婧,沈亚非,邓飞.达格列净联合胰岛素强化治疗血糖控制不佳2型糖尿病的临床研究[J].中国实用医刊,2019(19):93-96.[9]曲建昌,王彤,李丽,等.维格列汀联合二甲双胍对超重2型糖尿病病人代谢指标的影响[J].安徽医药,2019,23(4):819-822.[10]高文娟,李朋梅,赵莉.2型糖尿病住院患者恩格列净不良反应发生情况分析[J].药物不良反应杂志,2021,23(6):293-297.[11]冯建军.恩格列净联合利拉鲁肽治疗2型糖尿病的临床疗效观察[J].中国药物与临床,2021,21(10):1744-1746.[12]程雪梅,戚筠.甘精胰岛素联合GLP-1受体激动剂对2型糖尿病患者胰岛素功能及血糖的影响[J].药物生物技术,2020,27(2):127-130.[13]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志,2021,13(4):315-409.[14]李庞敏,毛培军,黄倩,等.胰岛素联合达格列净治疗2型糖尿病临床疗效分析[J].陕西医学杂志,2020,49(11):1499-1502.[15]刘向阳,曹宏伟,赖敬波,等.恩格列净联合二甲双胍治疗新诊断超重及肥胖2型糖尿病的临床观察[J].解放军医药杂志,2020,32(9):26-29.[16]刘天碧,门鹏,翟所迪.恩格列净治疗2型糖尿病的有效性和安全性的循证评价[J].中国新药杂志,2019,28(7):877-885.[17]张晓旸.恩格列净对比格列美脲治疗2型糖尿病的疗效以及安全性评价[J].中国药物与临床,2019,19(12):1965-1968.[18]彭湾湾,薛君力.恩格列净联合胰岛素强化治疗肥胖2型糖尿病患者的疗效与安全性[J].实用医学杂志,2019,35(20):3223-3226.[19]孙艳,代丹娇,陈智伟,等.利拉鲁肽和恩格列净联合胰岛素治疗2型糖尿病的效果研究[J].河北医药,2020,42(21):3318-3320.

相似文献/References:

[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
　HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(18):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
　DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Journal of Medical Information,2018,31(18):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的 相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
　CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Journal of Medical Information,2018,31(18):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
　JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(18):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
　LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Journal of Medical Information,2018,31(18):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[6]刘静波,黄 萍,赵 静.应用微信平台对初发中青年2型糖尿病患者进行 健康管理模式的研究[J].医学信息,2018,31(14):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
　LIU Jing-bo,HUANG Ping,ZHAO Jing.Study on the Health Management Model of Young and Middle-aged Patients with Type 2 Diabetes Mellitus by WeChat Platform[J].Journal of Medical Information,2018,31(18):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
[7]丁 星,赵 畅,张海严,等.麦邦数据远程传输型血糖仪临床测量准确性的评价研究[J].医学信息,2018,31(15):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
　DING Xing,ZHAO Chang,ZHANG Hai-yan,et al.Evaluation of Accuracy of Clinical Measurement of Maibang Remote Data Transmission Glucometer[J].Journal of Medical Information,2018,31(18):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
[8]梁延洋,程艳娜,华柏慧,等.胃癌合并2型糖尿病术后血糖改善的临床观察[J].医学信息,2018,31(17):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
　LIANG Yan-yang,CHENG Yan-na,HUA Bai-hui,et al.Clinical Observation of Postoperative Blood Glucose Improvement in Patients with Gastric Cancer Complicated with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(18):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
[9]刘小红.长效胰岛素联合口服降糖药治疗2型糖尿病的 疗效与安全性评价[J].医学信息,2018,31(18):121.[doi:10.3969/j.issn.1006-1959.2018.18.038]
　LIU Xiao-hong.Efficacy and Safety of Long Acting Insulin Combined with Oral Hypoglycemic Agents in Treatment of Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(18):121.[doi:10.3969/j.issn.1006-1959.2018.18.038]
[10]鲍 哲,杨升伟,柯赛赛,等.益生元对2型糖尿病患者糖脂代谢的影响[J].医学信息,2018,31(18):132.[doi:10.3969/j.issn.1006-1959.2018.18.042]
　BAO Zhe,YANG Sheng-wei,KE Sai-sai,et al.Effect of Prebiotics on Glucose and Lipid Metabolism in Patients with Type 2 Diabetes mellitus[J].Journal of Medical Information,2018,31(18):132.[doi:10.3969/j.issn.1006-1959.2018.18.042]

更新日期/Last Update: 1900-01-01